Match tier Likely match
Presence Current · Arkansas
Last published 2023
Sources OpenAlex · ORCID
Refreshed 2026-08-15

Mahmoud Kiaei

This is a likely match — the affiliation was inferred from OpenAlex, ORCID, and web sources but has not been fully confirmed. Treat with appropriate caution.

Researcher

Also affiliated: NewYork–Presbyterian Hospital (2004–2011); Cornell University (2002–2013); Konkuk University (2006); University of Arkansas Medical Center (2016–2021); New York Hospital Queens (2004–2011); Oklahoma Medical Research Foundation (2006); Presbyterian Hospital (2004–2011); Center for Neurosciences (2015); Center for Translational Molecular Medicine (2016); BioVentures (United States) (2021); NewGen Therapeutics (United States) (2021–2023); Institute of Molecular Biology and Biophysics (2016); Arkansas Department of Agriculture (2023); Hannover Re (Germany) (2006); Icahn School of Medicine at Mount Sinai (2004)

Faculty Researcher

33 h-index 56 pubs 4,898 cited

  • Animals
  • Amyotrophic Lateral Sclerosis
  • Humans
  • Mice
  • Mice, Transgenic
  • Disease Models, Animal
  • Superoxide Dismutase
  • Spinal Cord
  • Male
  • Female
  • Mutation
  • Superoxide Dismutase-1
  • Profilins
  • Motor Neurons
  • Neuroprotective Agents

Biography and Research Information

OverviewAI-generated summary

Mahmoud Kiaei's research focuses on understanding the molecular mechanisms underlying neurodegenerative diseases, particularly amyotrophic lateral sclerosis (ALS). His work utilizes a combination of computational and experimental approaches to investigate the structural and functional consequences of genetic mutations associated with ALS. This includes in silico studies to predict how mutations in proteins like profilin-1 and TUBA4A affect protein structure and interactions with potential therapeutic agents, such as riluzole and edaravone.

Kiaei also employs biochemical techniques, including hydrogen/deuterium exchange mass spectrometry, to detect structural and conformational changes in mutant proteins in vitro and in vivo. His research has explored the potential of RNA as a biomarker for ALS and investigated the aggregation of mutant profilin-1. Collaborations with researchers at the University of Arkansas for Medical Sciences and the University of Arkansas at Fayetteville contribute to his ongoing investigations. Kiaei's publication record includes studies on disease models, protein structure, and the development of therapeutic strategies for neurological disorders.

Metrics

  • h-index: 33
  • Publications: 56
  • Citations: 4,898

Selected Publications

  • A systematic review of emerging technologies to enhance the treatment of ovarian cancer (2023)
    Pharmaceutical Development and Technology 3 citations DOI OpenAlex
  • In silico analysis of TUBA4A mutations in Amyotrophic Lateral Sclerosis to define mechanisms of microtubule disintegration (2023)
    Scientific Reports 14 citations DOI OpenAlex
  • Correction to: RNA as a Source of Biomarkers for Amyotrophic Lateral Sclerosis (2022)
    Metabolic Brain Disease DOI OpenAlex
  • Detection of Structural and Conformational Changes in ALS-Causing Mutant Profilin1 With Hydrogen/Deuterium Exchange Mass Spectrometry and Bioinformatics Techniques (2021)
    Research Square 4 citations DOI OpenAlex
  • RNA as a source of biomarkers for amyotrophic lateral sclerosis (2021)
    Metabolic Brain Disease 4 citations DOI OpenAlex
  • Mutant Profilin1 Aggregation in Amyotrophic Lateral Sclerosis: An in Vivo Biochemical Analysis (2021)
    Basic and Clinical Neuroscience Journal 4 citations DOI OpenAlex
  • In silico studies reveal structural deviations of mutant profilin-1 and interaction with riluzole and edaravone in amyotrophic lateral sclerosis (2021)
    Scientific Reports 30 citations DOI OpenAlex
  • Detection of structural and conformational changes in ALS-causing mutant profilin-1 with hydrogen/deuterium exchange mass spectrometry and bioinformatics techniques (2021)
    Metabolic Brain Disease 6 citations DOI OpenAlex
  • Changes in biophysical characteristics of PFN1 due to mutation causing amyotrophic lateral sclerosis (2018)
    Metabolic Brain Disease 14 citations DOI OpenAlex
  • RNA-Seq Analysis of Spinal Cord Tissues from hPFN1G118V Transgenic Mouse Model of ALS at Pre-symptomatic and End-Stages of Disease (2018)
    Scientific Reports 13 citations DOI OpenAlex
  • ALS-causing mutations in profilin-1 alter its conformational dynamics: A computational approach to explain propensity for aggregation (2018)
    Scientific Reports 19 citations DOI OpenAlex
  • Antisense-mediated reduction of EphA4 in the adult CNS does not improve the function of mice with amyotrophic lateral sclerosis (2018)
    Neurobiology of Disease 30 citations DOI OpenAlex
  • Mutant Profilin1 transgenic mice recapitulate cardinal features of motor neuron disease (2016)
    Human Molecular Genetics 90 citations DOI OpenAlex
  • Profilin1 biology and its mutation, actin(g) in disease (2016)
    Cellular and Molecular Life Sciences 123 citations DOI OpenAlex
  • A retrospective review of the progress in amyotrophic lateral sclerosis drug discovery over the last decade and a look at the latest strategies (2015)
    Expert Opinion on Drug Discovery 31 citations DOI OpenAlex

View all publications on OpenAlex →

Collaboration Network

14 Collaborators 9 Institutions 2 Countries

Top Collaborators

View profile →

Similar Researchers

Based on overlapping research topics